Minnelide is an effective therapy against pancreatic cancer. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants. Minnelide reduced tumor volume in multiple models of pancreatic cancer. Minnelide was a more effective drug against pancreatic cancer models. It effectively reduced tumor burden and tumor related morbidity in different unique but complementary mouse models. It reduced metastatic spread and increased survival in the different models as well.

Minnelide is a water-soluble tretinoin lactone prodrug with anticancer and antitumor activity that induces apoptosis and may prevent podocyte damage.Minnelide inhibits cervical cancer growth by blocking HPV-induced changes in p53 and pRb.